Kirkland & Ellis has advised Axera Semiconductor Co., Ltd. Clifford Chance has advised the joint sponsors CICC, GTJA and BOCOM and the underwriters. Axera Semiconductor Co.,...
Axera Semiconductor Completes US$379 Million IPO and Listing on Hong Kong Stock Exchange
Ribo Life Science Completes HK$1.83 Billion Hong Kong IPO
Kirkland & Ellis has advised Suzhou Ribo Life Science Co., Ltd. on its global offering and listing. O’Melveny & Myers has represented the joint sponsors CICC...
NovaBridge Biosciences Acquires VIS-101, Expanding Biologic Drug Portfolio
Kirkland & Ellis has advised CBC Group-backed NovaBridge Biosciences. NovaBridge Biosciences, supported by CBC Group, has completed the acquisition of VIS-101, a novel bifunctional biologic targeting...
Xuanzhu Biopharm Completes Spin-off and Separate Listing on Hong Kong Stock Exchange
Kirkland & Ellis has advised Sihuan Pharmaceutical Holdings Group Ltd. and Xuanzhu Biopharmaceutical Co., Ltd. on the deals. Sihuan Pharmaceutical Holdings Group Ltd. and its subsidiary...
CF PharmTech Completes Hong Kong IPO Raising HK$607.7 Million
Kirkland & Ellis has advised CF PharmTech, Inc. CF PharmTech, Inc. has completed a global offering and listing on the Main Board of the Hong Kong...
Kelun-Biotech Completes HKD 1.943 Billion H-Share Placing
Kirkland & Ellis has advised the placing agents, including Goldman Sachs (Asia) L.L.C. and Citigroup Global Markets Limited on the deal. Zhong Lun, Sullivan & Cromwell,...